Contrasting ClearPoint Neuro (NASDAQ:CLPT) & Baird Medical Investment (NASDAQ:BDMD)

Baird Medical Investment (NASDAQ:BDMD) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Earnings & Valuation

This table compares Baird Medical Investment and ClearPoint Neuro”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baird Medical Investment	$22.54 million	2.15	N/A	N/A	N/A
ClearPoint Neuro	$40.61 million	13.82	-$25.54 million	($1.01)	-18.53

Baird Medical Investment has higher earnings, but lower revenue than ClearPoint Neuro.

Analyst Recommendations

This is a summary of current ratings for Baird Medical Investment and ClearPoint Neuro, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baird Medical Investment	1	0	0	0	1.00
ClearPoint Neuro	1	0	2	0	2.33

ClearPoint Neuro has a consensus price target of $23.00, indicating a potential upside of 22.86%. Given ClearPoint Neuro’s stronger consensus rating and higher possible upside, analysts clearly believe ClearPoint Neuro is more favorable than Baird Medical Investment.

Risk & Volatility

Baird Medical Investment has a beta of -1.17, meaning that its stock price is 217% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.

Profitability

This table compares Baird Medical Investment and ClearPoint Neuro’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Baird Medical Investment	N/A	N/A	N/A
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

Institutional and Insider Ownership

19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ClearPoint Neuro beats Baird Medical Investment on 7 of the 11 factors compared between the two stocks.

About Baird Medical Investment

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.

About ClearPoint Neuro

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.